PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
PTC Therapeutics's gross margin for the twelve months ending Dec 31, 2019 was 96.0%. For fiscal 2019 it was 96.0%, against 95.2% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 96.0% | +0.8 |
| FY2018 | Dec 31, 2018 | 95.2% | −2.4 |
| FY2017 | Dec 31, 2017 | 97.6% | −2.4 |
| FY2016 | Dec 31, 2016 | 100.0% | +0.0 |
| FY2015 | Dec 31, 2015 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | 96.3% | +0.7 |
| Q3 FY2019 | Sep 30, 2019 | 95.8% | +1.9 |
| Q2 FY2019 | Jun 30, 2019 | 96.2% | −0.0 |
| Q1 FY2019 | Mar 31, 2019 | 95.6% | +1.0 |
| Q4 FY2018 | Dec 31, 2018 | 95.6% | −0.2 |
| Q3 FY2018 | Sep 30, 2018 | 93.9% | −2.4 |
| Q2 FY2018 | Jun 30, 2018 | 96.3% | −2.2 |
| Q1 FY2018 | Mar 31, 2018 | 94.6% | −5.3 |
| Q4 FY2017 | Dec 31, 2017 | 95.8% | −4.2 |
| Q3 FY2017 | Sep 30, 2017 | 96.2% | – |
| Q2 FY2017 | Jun 30, 2017 | 98.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 99.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 100.0% | – |
See a number that looks wrong?